OOIR: Observatory of International Research

Papers

(The H4-Index of Experimental Hematology & Oncology is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Complex roles of cAMP–PKA–CREB signaling in cancer	244
CD44 as a tumor biomarker and therapeutic target	206
Role of m6A writers, erasers and readers in cancer	100
Research progress on dendritic cell vaccines in cancer immunotherapy	82
Heterogeneity of the tumor immune microenvironment and its clinical relevance	73
Breast cancer heterogeneity and its implication in personalized precision therapy	73
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies	72
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017	69
Engineering better chimeric antigen receptor T cells	68
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC	67
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment	62
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition	61
MiRNA-mediated EMT and CSCs in cancer chemoresistance	54
Recent advances and challenges of bispecific antibodies in solid tumors	52
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL	51
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia	44
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder	43
m6A binding protein YTHDF2 in cancer	41
Current insight into the regulation of PD-L1 in cancer	41
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma	41
Increasing cure rates of solid tumors by immune checkpoint inhibitors	40
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma	39
TRIM family contribute to tumorigenesis, cancer development, and drug resistance	39
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development	39
COVID-19 vaccination associated severe immune thrombocytopenia	38

Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients	37
Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A4	36
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors	36
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy	35
Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment	35
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy	34
TCR engineered T cells for solid tumor immunotherapy	33
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma	33